Murthy Simhambhatla

Murthy Simhambhatla was formerly the President and Chief Executive Officer of Evolus, a medical aesthetics company with a lead biologic drug, DWP-450, which he led towards an IPO in 2018. Prior to Evolus, Dr. Simhambhatla was a Senior Vice President at Abbott Laboratories and President of Abbott Medical Optics, a $1B-plus global ophthalmic business focused on cataract and refractive surgery.